Perspectives

Roadblocks to the use of blood-based biomarkers in clinical care

Why Alzheimer’s disease research is focusing on tau

Barriers to participation of underrepresented groups in clinical trials

How social media is shaping public opinion on scientific research

Understanding the global burden of dementia: challenges and opportunities

Studying the proteome in Alzheimer’s Disease

NE3107 properties and mode of action

Ongoing concerns regarding lecanemab: efficacy & adverse events

The future of focused ultrasound in AD

Prioritizing research on neuromodulatory subcortical systems for new insights in Alzheimer’s disease

Random forests in large-scale omics studies

Assessing clinical meaningfulness with ‘time saved’ in Alzheimer’s disease

Targeting the immune system in Alzheimer’s disease

How feasible is an Alzheimer’s disease blood test in the UK?

TREM2 as a target for disease modification in Alzheimer’s disease

Why have anti-amyloid monoclonal antibodies performed differently in Phase III trials